Ranbaxy Laboratories has received tentative approval from FDA to manufacture and market Galantamine Hydrobromide Tablets, 4mg (base), 8mg (base), and 12mg (base).
Ads by Google
Regence BlueCross BlueShield of Oregon has introduced a Generics First Antidepressant Program.
Lobbyists for the pharmaceutical industry increasingly are targeting state lawmakers as drug makers find themselves on the defensive.
San Francisco Chronicle examined the new field of direct-to-consumer genetic testing, including home-based paternity tests and tests that can determine the gender of a fetus.
WHO is moving to quickly replenish the dwindling pre-positioned stocks of life-saving medicines including oral rehydration salt packets, antibiotics and IV fluids to prevent deaths from diarrhoea in flood-affected Bangladesh.
If Rhode Island moves forward with a plan to impose prescription drug copayments on some Medicaid beneficiaries, the state should promote a federal law that provides no-cost prescription drugs for Medicaid beneficiaries who cannot afford copays, according to advocates for the elderly, low-income and people with disabilities, the Providence Journal reports (Gudrais, Providence Journal, 8/21).
FDA approved Risperdal for the treatment of schizophrenia in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder.
A Minnesota law requires pharmaceutical companies to report certain payments to physicians.
Eli Lilly program has helped Medicaid programs in Minnesota and other states monitor prescriptions for psychiatric medications
Medicare prescription drug benefit has significantly increased the share of seniors with drug coverage, but one in five beneficiaries reported delaying or not filling prescriptions because of cost.
Watson Pharmaceuticals has received final approval from FDA on its Abbreviated New Drug Application for fentanyl transdermal system.
FDA in recent months has rejected a slew of new drug applications or delayed approval of experimental medications and required more data.
Due in large part to strong competitive bidding by health and prescription drug plans and beneficiaries' choices, the Centers for Medicare and Medicaid Services (CMS) anticipates that the actual average premium paid by beneficiaries for standard Part D coverage in 2008 will be roughly $25.
A program will coordinate the delivery of medications during public health emergencies.
A coalition of physician, pharmacy, health insurer will conduct research and develop programs on the use of technology to help reduce medication errors.
FDA approved updated labeling for the widely used blood-thinning drug, Coumadin, to explain that people's genetic makeup may influence how they respond to the drug.
A collection of 35 small and medium-sized labor unions and local union shops are taking an aggressive step in addressing the cost of providing prescription drug coverage to their members.
FDA has accepted for review GlaxoSmithKline's Biologics License Application for Rotarix, an oral candidate vaccine for infants to prevent rotavirus gastroenteritis.
Avitar highlights the importance of the State of Hawaii's recent updating of their workplace drug testing laws to incorporate oral fluid-based on-site technology and its associated benefits.
The role pharmacists play as health care providers still remains unclear to the people who need them the most - elderly Americans with multiple medications for chronic diseases.
CMS on Monday announced that average monthly premiums for the Medicare drug benefit will increase to $25 in 2008, up from $22 in 2007, the Baltimore Sun reports (Baltimore Sun, 8/14). About 87% of beneficiaries will have access to prescription drug coverage at the same cost or less in 2008 than in 2007, according to CMS (CQ HealthBeat, 8/13). Beneficiaries can access prescription drugs with premiums at the 2007 level by enrolling in a different drug benefit plan during the open enrollment period, which begins Nov. 15 (AP/Detroit Free Press, 8/13).